Covetrus, Inc. (NASDAQ: CVET) Stock Competitors & Peer Comparison
See CVET's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CVET and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CVET | $20.99 | +0.00% | 0 | -69.97 | -$0.30 | N/A |
| MCK | $901.82 | +2.38% | 103.2B | 21.59 | $40.82 | +0.39% |
| COR | $325.62 | +1.46% | 62.6B | 18.75 | $17.15 | +0.75% |
| CAH | $234.57 | -0.61% | 54.9B | 22.49 | $10.43 | +0.87% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $88.35 | +1.20% | 10.1B | 16.64 | $5.31 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +2.49% |
| AHG | $0.81 | +10.79% | 678.6M | -3.72 | -$0.21 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
| EMPG | $17.36 | +0.00% | 143M | 192.89 | $0.09 | N/A |
Stock Comparison
McKesson Corporation (NYSE: MCK)
CVET vs MCK Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, MCK has a market cap of 103.2B. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while MCK trades at $901.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas MCK's P/E ratio is 21.59. In terms of profitability, CVET's ROE is -0.06%, compared to MCK's ROE of -1.94%. Regarding short-term risk, CVET is more volatile compared to MCK. This indicates higher risk in terms of short-term price fluctuations for CVET.Check MCK's competition here
Cencora, Inc. (NYSE: COR)
CVET vs COR Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, COR has a market cap of 62.6B. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while COR trades at $325.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas COR's P/E ratio is 18.75. In terms of profitability, CVET's ROE is -0.06%, compared to COR's ROE of +1.06%. Regarding short-term risk, CVET is more volatile compared to COR. This indicates higher risk in terms of short-term price fluctuations for CVET.Check COR's competition here
Cardinal Health, Inc. (NYSE: CAH)
CVET vs CAH Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, CAH has a market cap of 54.9B. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while CAH trades at $234.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas CAH's P/E ratio is 22.49. In terms of profitability, CVET's ROE is -0.06%, compared to CAH's ROE of -0.60%. Regarding short-term risk, CVET is less volatile compared to CAH. This indicates lower risk in terms of short-term price fluctuations for CVET.Check CAH's competition here
AmerisourceBergen Corporation (NYSE: ABC)
CVET vs ABC Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas ABC's P/E ratio is 21.92. In terms of profitability, CVET's ROE is -0.06%, compared to ABC's ROE of +1.06%. Regarding short-term risk, CVET is less volatile compared to ABC. This indicates lower risk in terms of short-term price fluctuations for CVET.Check ABC's competition here
Henry Schein, Inc. (NASDAQ: HSIC)
CVET vs HSIC Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, HSIC has a market cap of 10.1B. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while HSIC trades at $88.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas HSIC's P/E ratio is 16.64. In terms of profitability, CVET's ROE is -0.06%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, CVET is more volatile compared to HSIC. This indicates higher risk in terms of short-term price fluctuations for CVET.Check HSIC's competition here
Patterson Companies, Inc. (NASDAQ: PDCO)
CVET vs PDCO Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas PDCO's P/E ratio is 20.48. In terms of profitability, CVET's ROE is -0.06%, compared to PDCO's ROE of +0.18%. Regarding short-term risk, CVET is more volatile compared to PDCO. This indicates higher risk in terms of short-term price fluctuations for CVET.Check PDCO's competition here
Akso Health Group (NASDAQ: AHG)
CVET vs AHG Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, AHG has a market cap of 678.6M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while AHG trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas AHG's P/E ratio is -3.72. In terms of profitability, CVET's ROE is -0.06%, compared to AHG's ROE of -0.50%. Regarding short-term risk, CVET is more volatile compared to AHG. This indicates higher risk in terms of short-term price fluctuations for CVET.Check AHG's competition here
Owens & Minor, Inc. (NYSE: OMI)
CVET vs OMI Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas OMI's P/E ratio is -0.47. In terms of profitability, CVET's ROE is -0.06%, compared to OMI's ROE of +0.63%. Regarding short-term risk, CVET is less volatile compared to OMI. This indicates lower risk in terms of short-term price fluctuations for CVET.Check OMI's competition here
Empro Group Inc. Ordinary shares (NASDAQ: EMPG)
CVET vs EMPG Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, EMPG has a market cap of 143M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while EMPG trades at $17.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas EMPG's P/E ratio is 192.89. In terms of profitability, CVET's ROE is -0.06%, compared to EMPG's ROE of +0.66%. Regarding short-term risk, CVET is more volatile compared to EMPG. This indicates higher risk in terms of short-term price fluctuations for CVET.Check EMPG's competition here
Accendra Health, Inc. (NYSE: ACH)
CVET vs ACH Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, ACH has a market cap of 82.7M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while ACH trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas ACH's P/E ratio is 1.59. In terms of profitability, CVET's ROE is -0.06%, compared to ACH's ROE of +0.63%. Regarding short-term risk, CVET is less volatile compared to ACH. This indicates lower risk in terms of short-term price fluctuations for CVET.Check ACH's competition here
Akso Health Group (NASDAQ: HX)
CVET vs HX Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas HX's P/E ratio is -1.84. In terms of profitability, CVET's ROE is -0.06%, compared to HX's ROE of -1.07%. Regarding short-term risk, CVET is less volatile compared to HX. This indicates lower risk in terms of short-term price fluctuations for CVET.Check HX's competition here
111, Inc. (NASDAQ: YI)
CVET vs YI Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, YI has a market cap of 31.1M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while YI trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas YI's P/E ratio is -2.54. In terms of profitability, CVET's ROE is -0.06%, compared to YI's ROE of +0.14%. Regarding short-term risk, CVET is more volatile compared to YI. This indicates higher risk in terms of short-term price fluctuations for CVET.Check YI's competition here
Wellgistics Health, Inc. (NASDAQ: WGRX)
CVET vs WGRX Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, WGRX has a market cap of 8.7M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while WGRX trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas WGRX's P/E ratio is -0.33. In terms of profitability, CVET's ROE is -0.06%, compared to WGRX's ROE of +8.78%. Regarding short-term risk, CVET is less volatile compared to WGRX. This indicates lower risk in terms of short-term price fluctuations for CVET.Check WGRX's competition here
Zynex, Inc. (NASDAQ: ZYXI)
CVET vs ZYXI Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, CVET's ROE is -0.06%, compared to ZYXI's ROE of +11.38%. Regarding short-term risk, CVET is more volatile compared to ZYXI. This indicates higher risk in terms of short-term price fluctuations for CVET.Check ZYXI's competition here
DataMEDS AI, Inc. (NASDAQ: MEDS)
CVET vs MEDS Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, MEDS has a market cap of 2.4M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while MEDS trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas MEDS's P/E ratio is N/A. In terms of profitability, CVET's ROE is -0.06%, compared to MEDS's ROE of +8.78%. Regarding short-term risk, CVET is less volatile compared to MEDS. This indicates lower risk in terms of short-term price fluctuations for CVET.Check MEDS's competition here
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD)
CVET vs HKPD Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, HKPD has a market cap of 1.3M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while HKPD trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas HKPD's P/E ratio is -2.04. In terms of profitability, CVET's ROE is -0.06%, compared to HKPD's ROE of -0.15%. Regarding short-term risk, CVET is more volatile compared to HKPD. This indicates higher risk in terms of short-term price fluctuations for CVET.Check HKPD's competition here
Synergy CHC Corp. (NASDAQ: SNYR)
CVET vs SNYR Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, SNYR has a market cap of 1.1M. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while SNYR trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas SNYR's P/E ratio is -0.07. In terms of profitability, CVET's ROE is -0.06%, compared to SNYR's ROE of +0.91%. Regarding short-term risk, CVET is more volatile compared to SNYR. This indicates higher risk in terms of short-term price fluctuations for CVET.Check SNYR's competition here
Ridgetech, Inc. (NASDAQ: RDGT)
CVET vs RDGT Comparison September 2026
Covetrus, Inc. (NASDAQ: CVET) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CVET stands at 0. In comparison, RDGT has a market cap of 745.1K. Regarding current trading prices, CVET is priced at $20.99 on the NASDAQ, while RDGT trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CVET currently has a P/E ratio of -69.97, whereas RDGT's P/E ratio is -0.02. In terms of profitability, CVET's ROE is -0.06%, compared to RDGT's ROE of -0.04%. Regarding short-term risk, CVET is more volatile compared to RDGT. This indicates higher risk in terms of short-term price fluctuations for CVET.Check RDGT's competition here